TYRA
NASDAQTyra Biosciences Inc.
News · 26 weeks59-31%
2025-12-142026-06-07
Mix4190d
- Insider18(44%)
- SEC Filings10(24%)
- Other8(20%)
- Analyst3(7%)
- Leadership2(5%)
Latest news
25 items- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 4 filed by Director Simson Jake4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 4 filed by Director Moran Susan4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 4 filed by Director Verjee Rehan4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 4 filed by Director Gulfo Adele M.4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 4 filed by Director Rothenberg Stephen Michael4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 4 filed by Director More Robert J4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECSEC Form 144 filed by Tyra Biosciences Inc.144 - Tyra Biosciences, Inc. (0001863127) (Subject)
- PRTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer-CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).UTUC is a rare cancer affecting the lining of the kidneys and ureters, with a high prevalence of activating FGFR3 alterations. St
- ANALYSTWolfe Research initiated coverage on Tyra BiosciencesWolfe Research initiated coverage of Tyra Biosciences with a rating of Peer Perform
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form 10-Q filed by Tyra Biosciences Inc.10-Q - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECTyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- PRTyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH -- First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 -- Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) -- Cash, cash equivalents and marketable securities of $383.5 million at Q1 2026; runway into 2H 2028 -CARLSBAD, Calif., May 13, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that targe
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- INSIDERChief Medical Officer Warner Douglas J was granted 25,000 shares (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERPresident and CEO Harris Todd was granted 79,000 shares, increasing direct ownership by 6% to 1,437,631 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERChief Financial Officer Fuhrman Alan was granted 20,000 shares, increasing direct ownership by 124% to 36,164 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERVice President, Finance (PAO) Rueb Yuliya was granted 8,333 shares, increasing direct ownership by 24% to 43,354 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERChief Operating Officer Ashar Bhavesh was granted 15,013 shares (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- PRTyra Biosciences to Participate in Upcoming Investor ConferencesCARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:BofA Securities Health Care Conference 2026Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PTLocation: Las Vegas, NVTD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside chat with Tyler van BurenPresentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ETLo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
TYRA FAQ
7 questionsWhat does Tyra Biosciences Inc. do?
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad...Where does TYRA stock trade?
Tyra Biosciences Inc. (TYRA) is listed on NASDAQ.What sector and industry is TYRA in?
Tyra Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tyra Biosciences Inc. go public?
Tyra Biosciences Inc. (TYRA) completed its IPO in 2021.What are analysts saying about TYRA?
Tyra Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-05-19. Recent price targets range from $3300.00 to $3500.00.What companies are similar to TYRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TYRA side-by-side with any of them on Quantisnow.How can I track TYRA on Quantisnow?
Quantisnow aggregates Tyra Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TYRA to receive live email and push alerts on every new disclosure.